Lisa Bollinger, chief medical officer at Polaryx, discusses signs that regulatory agencies are taking the issues related to rare disease therapy development seriously.
Lisa Bollinger
Advertisement
Lisa Bollinger is chief medical officer at Polaryx.
Articles by Lisa Bollinger
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Deepening Ties: Why China is Becoming Big Pharma's Most Essential R&D Partner
2
GSK Enters $10.6 Billion Agreement to Acquire Nuvalent Inc.
3
Pharma Funding Roundup: City Therapeutics Closes $99.5 Million Series B, Eloxx Pharmaceuticals Announces Pricing of $66 Million Public Offering
4
Pharmaceutical Executive Daily: GSK Acquires Nuvalent for $10.6 Billion
5